The tumor-associated antigen 90K/Mac-2-binding protein secreted by human colon carcinoma cells enhances extracellular levels of promatrilysin and is a novel substrate of matrix metalloproteinases-2, -7 (matrilysin) and -9: Implications of proteolytic cleavage

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 3, 2010, Pages 336-343

  Ulmer, Tricia A ^a   Keeler, Vicki ^a   André, Sabine ^b   Gabius, Hans Joachim ^b   Loh, Lambert ^a   Laferté, Suzanne ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Colon cancer; Galectin 3; Matrix metalloproteinases; Tumor associated antigen 90K

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; GALECTIN 3; GELATINASE A; GELATINASE B; LAMININ 1; LAMININ 10; MATRILYSIN; METALLOPROTEINASE; PROMATRILYSIN; SCLEROPROTEIN; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN 90K; UNCLASSIFIED DRUG; BINDING PROTEIN; MAC 2 BINDING PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; BINDING ASSAY; CANCER CELL CULTURE; CONFERENCE PAPER; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN CLEAVAGE; SEQUENCE ANALYSIS;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENZYME PRECURSORS; HUMANS; KINETICS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; METALLOENDOPEPTIDASES; PEPTIDE FRAGMENTS; PROGNOSIS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VACCINIA VIRUS;

EID: 76749118044     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.07.030     Document Type: Article

References (70)

1. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
2. Iqbal S., and Lenz H.J. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother. Pharmacol. 54 Suppl. 1 (2004) S32-S39
3. Meyerhardt J.A., and Mayer R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352 (2005) 476-487
4. Weir H.K., Thun M.J., Hankey B.F., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 95 (2003) 1276-1299
5. Iacobelli S., Arno E., D′Orazio A., and Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 46 (1986) 3005-3010
6. Linsley P.S., Horn D., Marquardt H., et al. Identification of a novel serum protein secreted by lung carcinoma cells. Biochemistry 25 (1986) 2978-2986
7. Koths K., Taylor E., Halenbeck R., Cassipit C., and Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J. Biol. Chem. 268 (1993) 14245-14249
8. Künzli B.M., Berberat P.O., Zhu Z.W., et al. Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2-binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma. Cancer 94 (2002) 228-239
9. Marchetti A., Tinari N., Butitta F., et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res. 62 (2002) 2535-2539
10. Ozaki Y., Kintani K., Hanaoka J., et al. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 95 (2002) 1954-1962
11. Park Y.P., Choi S.C., Kim J.H., et al. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int. J. Cancer 120 (2007) 813-820
12. Iacobelli S., Bucci I., D'Egidio M., et al. Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett. 319 (1993) 59-65
13. Natoli C., Garufi C., Tinari N., et al. Dynamic test with recombinant interferon-α2b: effect on 90K and other tumor-associated antigens in cancer patients without evidence of disease. Br. J. Cancer 67 (1993) 564-567
14. Iacobelli S., Sismondi M., Giai M., et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br. J. Cancer 69 (1994) 172-176
15. Greco C., Vona R., Cosimelli M., et al. Cell surface overexpression of galectin-3 and the presence of its ligand 90K in the blood plasma as determinants in colon neoplastic lesions. Glycobiology 14 (2004) 783-792
16. Friedman J., Trahey M., and Weissman I. Cloning and characterization of cyclophilin C-associated protein: a candidate natural cellular ligand for cyclophilin C. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 6815-6819
17. Chicheportiche Y., and Vassalli P. Cloning and expression of a mouse macrophage cDNA coding for a membrane glycoprotein of the scavenger receptor cysteine-rich domain family. J. Biol. Chem. 269 (1994) 5512-5517
18. Powell T.J., Schreck R., McCall M., et al. A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J. Immunother. 17 (1995) 209-221
19. Trahey M., and Weissman I.L. Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3006-3011
20. Fukaya Y., Shimada H., Wang L.C., Zandi E., and DeClerck Y.A. Identification of Gal-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J. Biol. Chem. 283 (2008) 18573-18581
21. Kong W., Longaker M.T., and Lorenz H.P. Cyclophilin C-associated protein is a mediator for fibronectin fragment-induced matrix metalloproteinase-13 expression. J. Biol. Chem. 279 (2004) 5334-5340
22. Sasaki T., Brakebusch C., Engel J., and Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds β1-integrins, collagens and fibronectin. EMBO J. 17 (1998) 1606-1613
23. Müller S.A., Sasaki T., Bork P., et al. Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures. J. Mol. Biol. 291 (1999) 801-813
24. Hellstern S., Sasaki T., Fauser C., Lustig A., Timpl R., and Engel J. Functional studies on recombinant domains of Mac-2 binding protein. J. Biol. Chem. 277 (2002) 15690-15696
25. Ulmer T., Keeler V., Loh L., et al. Tumor-associated antigen 90K/Mac-2 binding protein: possible role in colon cancer. J. Cell. Biochem. 98 (2006) 1351-1366
26. Solís D., Jiménez-Barbero J., Kaltner H., et al. Towards defining the role of glycans as hardware in information storage and transfer: basic principles, experimental approaches and recent progress. Cells Tissues Organs 168 (2001) 5-23
27. Gabius H.-J., Siebert H.-C., André S., Jiménez-Barbero J., and Rüdiger H. Chemical biology of the sugar code. ChemBioChem 5 (2004) 740-764
28. Gabius H.-J. Glycans: bioactive signals decoded by lectins. Biochem. Soc. Trans. 36 (2008) 1491-1496
29. André S., Kojima S., Yamazaki N., et al. Galectins-1 and -3 and their ligands in tumor biology. J. Cancer Res. Clin. Oncol. 125 (1999) 461-474
30. Gabius H.-J. Cell surface glycans: the why and how of their functionality as biochemical signals in lectin-mediated information transfer. Crit. Rev. Immunol. 26 (2006) 43-79
31. In: Gabius H.-J. (Ed). The Sugar Code. Fundamentals of Glycosciences (2009), Wiley/VCH, Weinheim
32. Villalobo A., Nogales-González A., and Gabius H.-J. A guide to signaling pathways connecting protein-glycan interaction with the emerging versatile effector functionality of mammalian lectins. Trends Glycosci. Glycotechnol. 18 (2006) 1-37
33. Laferté S., and Loh L.C. Characterization of a family of structurally related glycoproteins expressing β1-6 branched asparagine-linked oligosaccharides in human colon cancer cells. Biochem. J. 283 (1992) 193-201
34. Dennis J.W., Laferté S., Waghorne C., Breitman M.L., and Kerbel R.S. β1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236 (1987) 582-585
35. Dennis J.W., Granovsky M., and Warren C.E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473 (1999) 21-34
36. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3 (2003) 453-458
37. Canals F., Colome N., Ferrer C., Plaza-Calonge M., and Rodriguez-Manzaneque J.C. Identification of substrates of the extracellular protease ADAMTS1 by DIGE proteomic analysis. Proteomics 6 Suppl. 1 (2006) 28-35
38. Bair E.L., Nagle R.B., Ulmer T.A., Laferté S., and Bowden G.T. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate 66 (2006) 283-293
39. Zucker S., and Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 23 (2004) 101-117
40. Eng J.K., McCormick A.L., and Yates III J.R. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5 (1994) 976-989
41. Chittum H.S., Lane W.S., Carlson B.A., et al. Rabbit β-globin is extended beyond its UGA stop codon by multiple suppressions and translational reading gaps. Biochemistry 37 (1998) 10866-10870
42. Kopitz J., von Reitzenstein C., André S., et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J. Biol. Chem. 276 (2001) 35917-35923
43. André S., Kojima S., Gundel G., et al. Branching mode in complex-type triantennary N-glycans as regulatory element of their ligand properties. Biochim. Biophys. Acta 1760 (2006) 768-782
44. Zeng F.-Y., Gerke V., and Gabius H.-J. Identification of annexin II, annexin VI and glyceraldehyde-3-phosphate dehydrogenase as calcyclin-binding proteins in bovine heart. Int. J. Biochem. 7 (1993) 1019-1027
45. André S., Unverzagt C., Kojima S., et al. Determination of modulation of ligand properties of synthetic complex-type biantennary N-glycans by introduction of bisecting GlcNAc in silico, in vitro and in vivo. Eur. J. Biochem. 271 (2004) 118-134
46. Wagenaar-Miller R.A., Gorden L., and Matrisian L.M. Matrix metalloproteinases in colorectal cancer: is it worth talking about?. Cancer Metastasis Rev. 23 (2004) 119-135
47. Deryugina E., and Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25 (2006) 9-34
48. Roeb E., Arndt M., Jansen B., Schumpelick V., and Matern S. Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int. J. Colorectal Dis. 19 (2004) 518-524
49. Luo H.Z., Zhou Z.G., Yang L., et al. Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn. J. Clin. Oncol. 35 (2005) 739-744
50. Adachi Y., Yamamoto H., Itoh F., Hinoda Y., Okada Y., and Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 45 (1999) 252-258
51. Kurokawa S., Arimura Y., Yamamoto H., et al. Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers. Gut 54 (2005) 1751-1758
52. Maliner-Stratton M., Klein R., Udayakumar T., Nagle R., and Bowden G.T. Interleukin-1β-induced promatrilysin expression is mediated by NFκB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP. Neoplasia 3 (2001) 509-520
53. Netzel-Arnett S., Sang Q.X., Moore W.G., Navre M., Birkedal-Hansen H., and van Wart H.E. Comparative sequence specificities of human. 72-and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). Biochemistry 32 (1993) 6427-6432
54. Overall C. Molecular determinants of metalloproteinase substrate specificity. Mol. Biotechnol. 22 (2002) 51-86
55. Sasaki T., Gohring W., Mann K., et al. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J. Biol. Chem. 272 (1997) 9237-9243
56. Agnihotri R., Crawford H.C., Hirotaka H., Matrisian L.M., Havrda M.C., and Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J. Biol. Chem. 276 (2001) 28261-28267
57. Shirafuji Y., Tanabe H., Satchell D.P., Henschen-Edman A., Wilson C.L., and Ouellette A.J. Structural determinants of procryptdin recognition and cleavage by matrix metalloproteinase-7. J. Biol. Chem. 278 (2003) 7910-7919
58. Miyamoto S., Yano K., Sugimoto S., et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 64 (2004) 665-671
59. Vargo-Gogola T., Crawford H.C., Fingleton B., and Matrisian L.M. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch. Biochem. Biophys. 408 (2002) 155-161
60. Powell W.C., Fingleton B., Wilson C.L., Boothby M., and Matrisian L.M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9 (1999) 1441-1447
61. Yurchenco P.D., and Wadsworth W.G. Assembly and tissue function of early embryonic laminins and netrin. Curr. Opin. Cell Biol. 1 (2004) 572-579
62. Wierzbicka-Patynowski I., and Schwarzbauer J.E. The ins and outs of fibronectin matrix assembly. J. Cell Sci. 116 (2003) 3269-3276
63. INK4a: modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells. FEBS J. 274 (2007) 3233-3256
64. Laferté S., Loh L.C., and Keeler V. Monoclonal antibodies specific for human tumor-associated antigen 90K/Mac-2 binding protein: tools to examine protein conformation and function. J. Cell. Biochem. 77 (2000) 540-559
65. Ahmad N., Gabius H.-J., Kaltner H., et al. Thermodynamic binding studies of cell surface carbohydrate epitopes to galectins-1, -3, and -7: evidence for differential binding specificities. Can. J. Cancer 80 (2002) 1096-1104
66. Rapoport E.M., André S., Kurmyshkina O.V., et al. Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting. Glycobiology 18 (2008) 315-324
67. Unverzagt C., André S., Seifert J., et al. Structure-activity profiles of complex biantennary glycans with core fucosylation and with/without additional α2, 3/α2, 6 sialylation: synthesis of neoglycoproteins and their properties in lectin assays, cell binding, and organ uptake. J. Med. Chem. 45 (2002) 478-491
68. André S., Kojima S., Prahl I., Lensch M., Unverzagt C., and Gabius H.-J. Introduction of extended LEC14-type branching into core-fucosylated biantennary N-glycan. Glycoengineering for enhanced cell binding and serum clearance of the neoglycoproteins. FEBS J. 272 (2005) 1986-1998
69. André S., Kožár T., Schuberth R., Unverzagt C., Kojima S., and Gabius H.-J. Substitutions in the N-glycan core as regulators of biorecognition: the case of core-fucose and bisecting GlcNAc moieties. Biochemistry 46 (2007) 6984-6995
70. André S., Kožár T., Kojima S., Unverzagt C., and Gabius H.-J. From structural to functional glycomics: core substitutions as molecular switches for shape and lectin affinity of N-glycans. Biol. Chem. 390 (2009) 557-566